scholarly journals Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report

2020 ◽  
Vol 10 ◽  
Author(s):  
Giuseppe Tirino ◽  
Angelica Petrillo ◽  
Luca Pompella ◽  
Annalisa Pappalardo ◽  
Maria Maddalena Laterza ◽  
...  
Hernia ◽  
2002 ◽  
Vol 6 (2) ◽  
pp. 88-90 ◽  
Author(s):  
Tahir M. Oruç ◽  
Bahadir Kulah ◽  
Baris Saylam ◽  
Munevver Moran ◽  
Levent Albayrak ◽  
...  

2020 ◽  
Vol Volume 13 ◽  
pp. 867-876 ◽  
Author(s):  
Angelica Petrillo ◽  
Giuseppe Tirino ◽  
Federica Zito Marino ◽  
Luca Pompella ◽  
Rosalaura Sabetta ◽  
...  

Gut and Liver ◽  
2012 ◽  
Vol 6 (3) ◽  
pp. 388-394 ◽  
Author(s):  
Mi-Young Kim ◽  
Hwoon-Yong Jung ◽  
Kee Don Choi ◽  
Ho June Song ◽  
Jeong Hoon Lee ◽  
...  

2001 ◽  
Vol 62 (12) ◽  
pp. 2909-2912
Author(s):  
Takashi EMOTO ◽  
Kiyoshi YOSHIKAWA ◽  
Masahiro FUJIKAWA ◽  
Makoto FUJII ◽  
Eisaku HAMADA ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Giandomenico Roviello ◽  
Alberto D’Angelo ◽  
Raheleh Roudi ◽  
Roberto Petrioli ◽  
Enrico Mini

Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer. Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.


Sign in / Sign up

Export Citation Format

Share Document